

## WHY COLLABORATE WITH CSL?



**Global** Capabilities on your doorstep



**Work** with one of the world's leading biotech companies



**Funding** for successful proposals



**Access** to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise



Accelerate translation of your research to deliver new therapies to patients

# CSL Research Acceleration Initiative

Applications close 13th March 2020

CSL's Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and Australasian research organisations.

Applications are sought from researchers working in a CSL **Therapeutic Area** and a **Focus Area**, and that are amenable to or include a **Modality** listed below:

#### **THERAPEUTIC AREAS**

(emphasis on rare disease)

- Immunology
- Neurology
- Haematology
- Thrombosis
- Transplant
- Respiratory
- Cardiovascular/ Metabolic

#### **FOCUS AREAS**

- Novel drug targets
- Novel therapeutic candidates
- Novel strategies for treating disease

### **MODALITIES**

- Antibodies
- Protein therapeutics
- Gene therapies
- Cell therapies
- Small molecules not of interest

Successful applicants will receive up to \$250k p.a. for up to 2 years (max \$500k funding).

To apply please email jerome.wielens@unimelb.edu.au

Interested researchers are invited to attend an information session:

Mon 17<sup>th</sup> Feb, 10-11am @ Bio21 Auditorium, 30 Flemington Rd, Parkville or

Mon 17<sup>th</sup> Feb, 1-2pm, by webinar or Thurs 20<sup>th</sup> Feb 12.30-1.30pm, by webinar

For webinar links and further details please e-mail **Jerome Wielens** at **jerome.wielens@unimelb.edu.au**